Evidence map›Paper›PMID 41820521›Full record

ArticleScientific reports2026

MSCMF-DTB: a multi-scale cross-modal fusion framework for drug-target binding prediction.

Juan Huang, Yuxue Pan, Qu Chen

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Juan Huang *School of Biological and Chemical Engineering, Zhejiang University of Science and Technology, Hangzhou, 310023, People's Republic of China.
Yuxue Pan *School of Biological and Chemical Engineering, Zhejiang University of Science and Technology, Hangzhou, 310023, People's Republic of China.
Qu ChenSchool of Biological and Chemical Engineering, Zhejiang University of Science and Technology, Hangzhou, 310023, People's Republic of China. chenqu@zust.edu.cn.

Funding

Natural Science Foundation of Zhejiang Province LY19B060002
6 · The paper itself

Abstract

Predicting drug-target binding remains a central challenge in computational drug discovery, particularly due to the need for models that jointly capture molecular topology, chemical substructures, and protein sequence dependencies. We propose MSCMF-DTB, an end-to-end deep learning framework supporting both drug-target interaction (DTI) classification and drug-target affinity (DTA) regression. On the drug side, molecular graphs generated with RDKit are encoded using a DenseGCN module, while a parallel fingerprint channel captures fragment-level and compositional features. On the protein side, contextualized embeddings from TAPE-BERT are processed through a multi-scale 1D CNN to extract local sequence patterns. Cross-modal drug-protein relationships are modeled using cross-attention mechanism coupled with a tensor network for higher-order feature interaction. The fused representations are fed into an MLP for final prediction. Extensive experiments demonstrate that MSCMF-DTB achieves competitive and consistent performance across small- and large-scale datasets (Human, C. elegans, GPCR, BioSNAP, and DrugBank for DTI, and DAVIS and KIBA for DTA). Notably, on the large-scale DrugBank dataset for DTI prediction, MSCMF-DTB improved AUC and Recall by up to 3.2% and 6.1%, respectively, compared with the second-best model (DrugBAN). For DTA prediction, the model achieved stable performance on the large and heterogeneous KIBA dataset, with an MSE of 0.146, a Concordance Index of 0.886, and an r

Indexed as

Computational BiologyDeep LearningDrug DiscoveryProteinsAnimalsHumansPharmaceutical PreparationsProtein BindingPharmaceutical PreparationsProteinsCross-Attention MechanismCross-Modal FusionDrug–Target AffinityDrug–Target InteractionMolecular FingerprintsTensor Networks

Identifiers

PMID41820521
PMCPMC13103073

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.